161 related articles for article (PubMed ID: 25742791)
1. Identification of epipolythiodioxopiperazines HDN-1 and chaetocin as novel inhibitor of heat shock protein 90.
Song X; Zhao Z; Qi X; Tang S; Wang Q; Zhu T; Gu Q; Liu M; Li J
Oncotarget; 2015 Mar; 6(7):5263-74. PubMed ID: 25742791
[TBL] [Abstract][Full Text] [Related]
2. HDN-1 induces cell differentiation toward apoptosis in promyelocytic leukemia cells depending on its selective effect on client proteins of Hsp90.
Qi X; Zhang X; Liu X; Tang W; Dai J; Chen A; Lin Q; Zhu T; Li J
Toxicol Appl Pharmacol; 2021 Apr; 417():115459. PubMed ID: 33609515
[TBL] [Abstract][Full Text] [Related]
3. Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer.
Ueno T; Tsukuda K; Toyooka S; Ando M; Takaoka M; Soh J; Asano H; Maki Y; Muraoka T; Tanaka N; Shien K; Furukawa M; Yamatsuji T; Kiura K; Naomoto Y; Miyoshi S
Lung Cancer; 2012 Apr; 76(1):26-31. PubMed ID: 21996088
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
[TBL] [Abstract][Full Text] [Related]
5. SUV39H1 is a New Client Protein of Hsp90 Degradated by Chaetocin as a Novel C-Terminal Inhibitor of Hsp90.
Lian B; Lin Q; Tang W; Qi X; Li J
Biomol Ther (Seoul); 2021 Jan; 29(1):73-82. PubMed ID: 33162400
[TBL] [Abstract][Full Text] [Related]
6. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells.
Shelton SN; Shawgo ME; Matthews SB; Lu Y; Donnelly AC; Szabla K; Tanol M; Vielhauer GA; Rajewski RA; Matts RL; Blagg BS; Robertson JD
Mol Pharmacol; 2009 Dec; 76(6):1314-22. PubMed ID: 19741006
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
Weng SH; Tseng SC; Huang YC; Chen HJ; Lin YW
Biochem Pharmacol; 2012 Jul; 84(1):126-36. PubMed ID: 22480737
[TBL] [Abstract][Full Text] [Related]
8. Penicisulfuranol A, a novel C-terminal inhibitor disrupting molecular chaperone function of Hsp90 independent of ATP binding domain.
Dai J; Chen A; Zhu M; Qi X; Tang W; Liu M; Li D; Gu Q; Li J
Biochem Pharmacol; 2019 May; 163():404-415. PubMed ID: 30857829
[TBL] [Abstract][Full Text] [Related]
9. Anticancer activity of methylene blue via inhibition of heat shock protein 70.
Sanchala D; Bhatt LK; Pethe P; Shelat R; Kulkarni YA
Biomed Pharmacother; 2018 Nov; 107():1037-1045. PubMed ID: 30257315
[TBL] [Abstract][Full Text] [Related]
10. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
11. KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells.
Liu W; Vielhauer GA; Holzbeierlein JM; Zhao H; Ghosh S; Brown D; Lee E; Blagg BS
Mol Pharmacol; 2015 Jul; 88(1):121-30. PubMed ID: 25939977
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
13. Identifying a C-terminal ATP binding sites-based novel Hsp90-Inhibitor in silico: a plausible therapeutic approach in Alzheimer's disease.
Khalid S; Paul S
Med Hypotheses; 2014 Jul; 83(1):39-46. PubMed ID: 24785461
[TBL] [Abstract][Full Text] [Related]
14. Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer.
Hyun SY; Le HT; Nguyen CT; Yong YS; Boo HJ; Lee HJ; Lee JS; Min HY; Ann J; Chen J; Park HJ; Lee J; Lee HY
Sci Rep; 2018 Sep; 8(1):13924. PubMed ID: 30224681
[TBL] [Abstract][Full Text] [Related]
15. The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model.
Moses MA; Henry EC; Ricke WA; Gasiewicz TA
Cancer Prev Res (Phila); 2015 Mar; 8(3):249-57. PubMed ID: 25604133
[TBL] [Abstract][Full Text] [Related]
16. Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC).
Jeong CH; Park HB; Jang WJ; Jung SH; Seo YH
Bioorg Med Chem Lett; 2014 Jan; 24(1):224-7. PubMed ID: 24345447
[TBL] [Abstract][Full Text] [Related]
17. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
Ko JC; Chen HJ; Huang YC; Tseng SC; Weng SH; Wo TY; Huang YJ; Chiu HC; Tsai MS; Chiou RY; Lin YW
Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
[TBL] [Abstract][Full Text] [Related]
18. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.
Massey AJ; Williamson DS; Browne H; Murray JB; Dokurno P; Shaw T; Macias AT; Daniels Z; Geoffroy S; Dopson M; Lavan P; Matassova N; Francis GL; Graham CJ; Parsons R; Wang Y; Padfield A; Comer M; Drysdale MJ; Wood M
Cancer Chemother Pharmacol; 2010 Aug; 66(3):535-45. PubMed ID: 20012863
[TBL] [Abstract][Full Text] [Related]
19. Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration.
Zismanov V; Drucker L; Gottfried M
Anticancer Drugs; 2014 Oct; 25(9):998-1006. PubMed ID: 25153785
[TBL] [Abstract][Full Text] [Related]
20. Fungal mycotoxin penisuloxazin A, a novel C-terminal Hsp90 inhibitor and characteristics of its analogues on Hsp90 function related to binding sites.
Dai J; Zhu M; Qi X; Wang Y; Li H; Tang S; Wang Q; Chen A; Liu M; Gu Q; Li D; Li J
Biochem Pharmacol; 2020 Dec; 182():114218. PubMed ID: 32949584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
